[1] |
XU Wenhao, TIAN Xi, Aihetaimujiang·Anwaier , QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei.
A systematic review of current advancements of artificial intelligence in genitourinary cancers
[J]. China Oncology, 2022, 32(1): 68-74.
|
[2] |
XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia.
The advances in immunotherapy biomarkers of small cell lung cancer
[J]. China Oncology, 2021, 31(7): 635-639.
|
[3] |
SHI Maolin , BAI Yudi , WANG Chao , LI Siqi , ZHOU Daijun , PENG Jingjing , SUN Feifan , LI Dong , ZHANG Tao .
Effect of PD-L1 expression on the efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinoma and its mechanism
[J]. China Oncology, 2021, 31(4): 308-316.
|
[4] |
SHI Wanhong , ZOU Lei , KANG Qiang , WANG Junfeng , BAI Jianhua , JIN Yun , ZHANG Jie , ZHANG Xiaowen .
The influence of silencing leptin gene on the invasion and migration abilities of gallbladder cancer GBC-SD and OCUG cells
[J]. China Oncology, 2021, 31(11): 1050-1057.
|
[5] |
ZHAO Haiyun, WU Xiaohua.
Research progress of immunotherapy in ovarian cancer
[J]. China Oncology, 2020, 30(7): 538-545.
|
[6] |
WANG Jing, CHEN Jie, HU Chun, HUANG Cheng.
PI3K/AKT regulates the expression of PD-L1 via Nrf2 pathway in non-small cell lung cancer
[J]. China Oncology, 2020, 30(6): 419-427.
|
[7] |
ZHU Xiaodong, CHEN Siyuan.
Combination therapy of immune checkpoint inhibitors: from rationale to practice
[J]. China Oncology, 2020, 30(12): 969-976.
|
[8] |
XU Wencai, GUO Leiming, CUI Yingying, LIU Xiao, JIANG Yue, GE Hong.
The effect of lung stereotactic body radiotherapy on peripheral blood lymphocytes
[J]. China Oncology, 2020, 30(12): 1013-1016.
|
[9] |
LI Guoyu , HE Ming .
New progress in the research of immunotherapy for extensive-stage small cell lung cancer
[J]. China Oncology, 2020, 30(10): 826-833.
|
[10] |
PAN Zeyan, ZHAN Xianbao.
Current status and future strategies of chimeric antigen receptor T-cells in the treatment of pancreatic cancer
[J]. China Oncology, 2019, 29(7): 481-485.
|
[11] |
PAN Yingying, ZHOU Fei, ZHOU Caicun.
The perspects and challenges of immunotherapy for lung cancer
[J]. China Oncology, 2019, 29(4): 241-249.
|
[12] |
HE Chunfeng, ZHANG Qingchuan, LIU Yong.
Silencing rictor gene by RNA interference inhibits cell growth of human bladder cancer T24 in vitro and in vivo
[J]. China Oncology, 2019, 29(3): 193-200.
|
[13] |
CAO Xiaoshan, CONG Binbin.
The progress of treatment for triple-negative breast cancer in the era of precision medicine
[J]. China Oncology, 2019, 29(12): 971-976.
|
[14] |
YANG Yunsong, JIANG Yizhou, HU Xin, SHAO Zhimin.
Research progress of breast tumor microenvironment-targeted therapy
[J]. China Oncology, 2019, 29(12): 977-984.
|
[15] |
JI Peng, GONG Yue, DI Genhong.
Latest research progress on tumor-infiltrating lymphocytes in HER2-positive and triple-negative breast cancer
[J]. China Oncology, 2018, 28(12): 928-934.
|